Results 161 to 170 of about 24,853 (244)

Case Report: Ruxolitinib for systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome: two pediatric cases and literature review. [PDF]

Front Pediatr
Liu H, Wang Z, Zhang W.
europepmc   +1 more source

JAK Activation Drives MED15-Associated Melanocyte Dysfunction in Vitiligo Beyond Immune Cells. [PDF]

Clin Cosmet Investig Dermatol
Wu J, Ren Y, Cui J, He M, Zhang X, Li D, Zhang N.   +6 more
europepmc   +1 more source

Allele burden expansion in JAK2V617F and CALR‐mutated myeloproliferative neoplasms predicts disease progression and is associated with anagrelide treatment

HemaSphere, Volume 10, Issue 9, September 2026.
Zi Yun Ng, Laurane Cottin, Marine Demoy, Damien Luque Paz, Corentin Orvain, Wayne‐Corentin Lambert, Jean‐Christophe Ianotto, Eric Lippert, David M. Ross, Diana Iarossi, Alesia Khan, Daniel Lock, Catherine Truong, Kamel Laribi, Yun Fan Yang, Laura Li Gagnon, Valerie Ugo, Claire N. Harrison, Jennifer O'Sullivan   +18 more
wiley   +1 more source

Real-world patient characteristics and clinical outcomes in patients with myelofibrosis in Japan. [PDF]

PLoS One
Yasutomi Y, Takano M, Chen YC, Chen CC, Kim SW, McGuiness C, Slowley A, Kirito K.   +7 more
europepmc   +1 more source

Ruxolitinib Penetrates Blood Brain Barrier and Reduces the Cytokine Storm in Patients With Haemophagocytic Lymphohistiocytosis. [PDF]

J Cell Mol Med
Ji W, Qing K, Ren J, Xue K, Fang J, Wu S.   +5 more
europepmc   +1 more source

Semi-Mechanistic PK/PD Modeling of Platelets and Spleen Volume With Navitoclax in Combination With Ruxolitinib in Patients With Myelofibrosis. [PDF]

CPT Pharmacometrics Syst Pharmacol
Polepally AR, Goebel A, Patel M, Biesdorf C, Potluri J, Menon RM, Mensing S, Engelhardt B.   +7 more
europepmc   +1 more source

Ruxolitinib-Treated Myeloproliferative Neoplasms: Real-World Infectious Outcomes and Preventive Practices from a Single Center. [PDF]

Mediterr J Hematol Infect Dis
Aydin MS, Korkmaz G, Pamukcuoglu M, Guner HR, Ceran F, Dagdas S, Ozet G.   +6 more
europepmc   +1 more source

Tinea barbae following ruxolitinib cream application in a vitiligo patient: a case report. [PDF]

Front Med (Lausanne)
Romagnuolo M, Rossi LC, Tavoletti G, Germiniasi F, Grancini A, Moltrasio C, Marzano AV, Alberti-Violetti S.   +7 more
europepmc   +1 more source

Case Report: Hemophagocytic lymphohistiocytosis masquerading as drug-induced liver injury: successful treatment with low-dose ruxolitinib and glucocorticoids. [PDF]

Front Immunol
Dai Y, Zhang L, Zhong X, Zhao A, Niu T.
europepmc   +1 more source

Prospective, non-interventional study of ruxolitinib therapy in patients with polycythaemia vera - German real-world data (PaVe study). [PDF]

Ann Hematol
Griesshammer M, von der Heyde E, Schlag R, Schmidt B, Weniger S, Koenigsmann M, Stauch M, Gückel E, Baum V, Weide R.   +9 more
europepmc   +1 more source